Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Joanne Rogin"'
Autor:
Trevor Resnick, Joanne Rogin, Silvia Kochen, Yan Li, David Blum, Elinor Ben-Menachem, Patrício Soares-da-Silva, Laura Strom, Helena Gama, Todd Grinnell
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Objectives: To evaluate cutaneous allergic reactions in clinical trials of adjunctive eslicarbazepine acetate (ESL) for focal seizures. Materials and methods: Data were analyzed from three phase III randomized, double-blind, placebo-controlled studie
Autor:
Todd Grinnell, Robert T. Wechsler, Barry E. Gidal, Scott Mintzer, Elinor Ben-Menachem, Matthias Schwab, Joanne Rogin, Joana Moreira, Patricio Manuel Vieira Araujo Soares Da Silva, Mar Carreño, David Blum, Yan Li
Publikováno v:
Epilepsy Research. 141:83-89
To evaluate the effects of eslicarbazepine acetate (ESL) on lipid metabolism and to determine whether reduced statin exposure during ESL therapy has clinical consequences.We conducted a post-hoc analysis of pooled data for serum lipids (laboratory va
Autor:
Gregory L. Krauss, Joana Moreira, Eugen Trinka, Bassel Abou-Khalil, Christian E. Elger, Hailong Cheng, Joanne Rogin, Todd Grinnell, Victor Biton, Helena Gama, José Rocha, David Blum
Publikováno v:
Epilepsy & Behavior. 72:127-134
To assess the safety and efficacy of once-daily (QD) adjunctive eslicarbazepine acetate (ESL).This post-hoc pooled analysis of three randomized, placebo-controlled trials (2093-301, -302, -304) involved adults with refractory partial-onset seizures (
Autor:
Eva Andermann, Mar Carreño, Elinor Ben-Menachem, F. Rocha, Helena Gama, Joanne Rogin, David Blum, Robert Tosiello, Fernando Cendes, Todd Grinnell, William E. Rosenfeld, R. Eugene Ramsay, Patrício Soares-da-Silva, Patricia Penovich
Publikováno v:
Epilepsy Research. 169:106478
Objective To investigate the safety and tolerability of eslicarbazepine acetate (ESL), a once-daily oral anti-seizure drug (ASD), in older and younger adult patient populations. Methods Two post-hoc pooled data analyses were performed: one from three
Autor:
Patrício Soares-da-Silva, Jay Harvey, Joanne Rogin, Bassel Abou-Khalil, Michael R. Sperling, Hailong Cheng, Seung Bong Hong, Teresa G. Nunes, David Blum, Arnaud Biraben, Pedro A. Kowacs, Carlo Andrea Galimberti
Publikováno v:
Epilepsia
Objective To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in patients with refractory partial-onset seizures. Methods This randomized, placebo-controlled, double-blind, parallel-group, phase III study was conducted at
Autor:
James W. Wheless, Nancy Sherman, Bassel Abou-Khalil, Joanne Rogin, Glenn C. Pixton, Rajesh B. Shukla, Carl L. Roland, Kenneth W. Sommerville, Kevin Wolter
Publikováno v:
Epilepsia. 55(9)
Summary Objective Part 1 of this phase III study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study of caregiver administered diazepam auto-injector (AI) in subjects with acute repetitive seizures (ARS) and demonstr
Autor:
Joanne Rogin, Veeraindar Goli, Rajesh B. Shukla, James W. Wheless, Nancy Sherman, Kenneth W. Sommerville, Glenn C. Pixton, Bassel Abou-Khalil, Carl L. Roland, Kevin Wolter
Publikováno v:
Epilepsia. 54(11)
Purpose A diazepam auto‐injector (AI) has been developed for intramuscular administration to treat acute repetitive seizures (ARS). The objective of this study was to evaluate the efficacy and safety of the diazepam AI when administered by caregive
Autor:
Joanne Rogin
Publikováno v:
Epilepsy & Behavior. 1:454
Oxcarbazepine (Trileptal) has recently been approved in the United States for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in chil
Publikováno v:
Neurology. 34(7)
Patients with advanced cancer, previously untreated, were given 60 mg/m2 cisplatin plus 60 mg/m2 adriamycin by monthly intravenous injections. Signs and symptoms of a predominantly sensory peripheral neuropathy developed in 92% of the patients. Patie